AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Investigators found PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in children.
According to recent research from the Netherlands, "A clinical phase II trial with an experimental hexavalent outer membrane vesicle (OMV) vaccine (HexaMen) containing six different porin A (PorAs) was carried out in toddlers (2 to 3 years) and schoolchildren (7 to 8 years) in the Netherlands. HexaMen exists of two OMVs each containing three different PorA types. The serum bactericidal activity (SBA) after vaccination against the six PorAs was significantly different and was higher in toddlers than in schoolchildren."
"After vaccination, the SBA against P1.5-2,10 was four to six times higher than against P1.7-2,4," reported Clementien L. Vermont and collaborators at the Netherlands Vaccine Institute and the Erasmus Medical Center-Sophia. "The aim of this study was to test whether the differences in SBA could be explained by a difference in subtype-specific antibody avidity maturation. The avidity index (AI) of antibodies against three subtypes (PorA types P1.5-2,10; P1.12-1,13 and P1.7-2,4) was measured by ELISA and evaluated in relation to SBA. A significant avidity maturation for the 3 PorA subtypes was found."
"This ...